William Blair analyst Tim Lugo reiterated an Outperform rating on ARS Pharmaceuticals Inc (NASDAQ: SPRY).The analyst comments "We attended the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Raymond James Reiterates Strong Buy Rating on ARS Pharmaceuticals Inc (SPRY)November 10, 2025 7:28 AM ARS Pharmaceuticals, Inc. (SPRY) Misses Q3 EPS by 6cNovember 10, 2025 6:09 AM Form 10-Q ARS Pharmaceuticals, For: Sep 30November 10, 2025 6:05 AM Form 8-K ARS Pharmaceuticals, For: Nov 10November 10, 2025 6:03 AM ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)November 10, 2025 6:00 AM